Cobimetinib R-enantiomer
98%
- Product Code: 110282
CAS:
934660-94-3
| Molecular Weight: | 531.31 g./mol | Molecular Formula: | C₂₁H₂₁F₃IN₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Cobimetinib R-enantiomer is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is a selective inhibitor of MEK, a protein kinase involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer cells. By inhibiting MEK, it helps to slow down or stop the growth of cancer cells. This compound is particularly effective in combination with other targeted therapies, such as BRAF inhibitors, for treating advanced melanoma that harbors BRAF mutations. Its role in combination therapy enhances the overall therapeutic response and can improve patient outcomes by targeting multiple pathways involved in cancer progression. Research is also ongoing to explore its potential in treating other cancers where the MAPK/ERK pathway is implicated.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿184,350.00 |
+
-
|
Cobimetinib R-enantiomer
Cobimetinib R-enantiomer is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is a selective inhibitor of MEK, a protein kinase involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer cells. By inhibiting MEK, it helps to slow down or stop the growth of cancer cells. This compound is particularly effective in combination with other targeted therapies, such as BRAF inhibitors, for treating advanced melanoma that harbors BRAF mutations. Its role in combination therapy enhances the overall therapeutic response and can improve patient outcomes by targeting multiple pathways involved in cancer progression. Research is also ongoing to explore its potential in treating other cancers where the MAPK/ERK pathway is implicated.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :